Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray
Novo Nordisk has successfully obtained a Dutch court injunction to block the production and distribution of an unapproved compounded semaglutide nasal spray. This legal victory strengthens the company's patent protections for its popular GLP-1 diabetes and obesity treatments.
Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray Bailey Pemberton Sat, August 8, 2026 at 7:10 PM EDT 2 min read NVO +2.81% NVO +2.81% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in